by telrheum | Sep 29, 2024 | Ankylosing Spondylitis, Biologic Therapy, Spondyloarthritis
The study explored the long-term safety and effectiveness of Bimekizumab (BKZ), a monoclonal antibody designed to block two proteins involved in inflammation, IL-17A and IL-17F. This dual inhibition helps control the excessive inflammation seen in ankylosing...
by telrheum | Sep 28, 2024 | Biologic Therapy, Psoriasis, Psoriatic Arthritis
The article reports on the findings from a Phase 2 clinical trial that investigated the effectiveness of Deucravacitinib, a selective Tyrosine Kinase 2 (TYK2) inhibitor, in reducing pain in patients with active Psoriatic Arthritis (PsA). PsA is a chronic inflammatory...
by telrheum | Jun 24, 2024 | Biologic Therapy, Anti-TNF, IL-23 Inhibitors, Il-6 inhibitors, JAK Inhibitor, Rituximab
Background: Rheumatoid arthritis (RA) patients often face higher cardiovascular risks due to chronic inflammation. Biologic disease-modifying antirheumatic drugs (biologic drugs) help control this inflammation, especially in those who don’t respond well to...
by telrheum | Jun 21, 2024 | Biologic Therapy, Anti-TNF, Spondyloarthritis
This study investigated why some children with juvenile spondyloarthritis (JSpA) do not respond to TNF inhibitors (TNFi), a common treatment. Researchers analyzed data from patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA)...
by telrheum | Jun 16, 2024 | Biologic Therapy, JAK Inhibitor, systemic juvenile idiopathic arthritis
Background: Systemic juvenile idiopathic arthritis (sJIA) is a severe form of arthritis in children that can lead to serious complications like macrophage activation syndrome (MAS) and lung disease. Even with current treatments like steroids and IL-1 inhibitors, some...
by telrheum | May 27, 2024 | Autoimmune Diseases, Biologic Therapy, IgG4-Related Diseases, JAK Inhibitor
The article “Successful Treatment of Refractory IgG4-Related Disease with Tofacitinib: Experiences from 7 Patients” presents a study conducted at Peking University People’s Hospital. The study aimed to evaluate the effectiveness and safety of tofacitinib, a Janus...
